POST Online Media Lite Edition


Sanofi to buy vaccines biotech group Protein Sciences for $650m, maybe more

Staff Writer |
Sanofi is to buy privately-held U.S vaccines biotech company Protein Sciences for an initial amount of $650 million.

Article continues below

Under the terms of the agreement, Sanofi will make an upfront payment of $650 million for Protein Sciences, and pay up to $100 million upon the achievement of certain milestones.

"The acquisition of Protein Sciences will allow us to broaden our flu portfolio with the addition of a non-egg based vaccine," said David Loew, Sanofi executive vice president and head of Sanofi Pasteur, the company's vaccines arm.

Sanofi missed out to Johnson & Johnson on buying Switzerland's biotech Actelion in January - a $30 billion deal - and was also beaten in August last year by a $14 billion bid for cancer specialist Medivation from Pfizer.

What to read next

Sanofi Pasteur and Merck end their joint work on vaccines
Sanofi and Hanmi Pharmaceutical in worldwide license agreement
Sanofi sues Novo Nordisk over diabetes drugs in U.S.